Dennis Falzon

Summary

Affiliation: World Health Organization
Country: Switzerland

Publications

  1. doi request reprint Giving a voice to those who die young: the fatal impact of tuberculosis and HIV in South Africa
    Dennis Falzon
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Future Microbiol 5:1641-3. 2010
  2. doi request reprint Multidrug-resistant tuberculosis around the world: what progress has been made?
    Dennis Falzon
    Global TB Programme, World Health Organization, Geneva, Switzerland
    Eur Respir J 45:150-60. 2015
  3. doi request reprint Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data
    Dennis Falzon
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Lancet Infect Dis 13:690-7. 2013
  4. doi request reprint WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
    D Falzon
    Stop TB Dept, World Health Organization, Geneva 27, Switzerland
    Eur Respir J 38:516-28. 2011
  5. doi request reprint Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF
    Karin Weyer
    Stop TB Dept, World Health Organization, Geneva, Switzerland
    Eur Respir J 42:252-71. 2013
  6. pmc Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010
    Matteo Zignol
    Stop TB Department, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
    Bull World Health Organ 90:111-119D. 2012
  7. pmc Multidrug-resistant tuberculosis in children: evidence from global surveillance
    Matteo Zignol
    World Health Organization, Geneva, Switzerland
    Eur Respir J 42:701-7. 2013
  8. doi request reprint Global epidemiology of tuberculosis
    Philippe Glaziou
    Stop TB Department STB, HIV AIDS, TB, Malaria and Neglected Tropical Diseases Cluster HTM, World Health Organization, Geneva, Switzerland
    Semin Respir Crit Care Med 34:3-16. 2013
  9. pmc Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing
    Matteo Zignol
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Clin Infect Dis 52:901-6. 2011
  10. pmc WHO guidance on electronic systems to manage data for tuberculosis care and control
    Hazim Timimi
    Stop TB Department, World Health Organization, Geneva, Switzerland
    J Am Med Inform Assoc 19:939-41. 2012

Collaborators

Detail Information

Publications15

  1. doi request reprint Giving a voice to those who die young: the fatal impact of tuberculosis and HIV in South Africa
    Dennis Falzon
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Future Microbiol 5:1641-3. 2010
    ..The investigative methodology used by the authors could be more widely applied to advocate for lifesaving measures in other settings sharing similar epidemiological challenges...
  2. doi request reprint Multidrug-resistant tuberculosis around the world: what progress has been made?
    Dennis Falzon
    Global TB Programme, World Health Organization, Geneva, Switzerland
    Eur Respir J 45:150-60. 2015
    ..Although progress has been noted in the expansion of MDR-TB care, urgent efforts are required in order to provide wider access to diagnosis and treatment in most countries with the highest burden of MDR-TB. ..
  3. doi request reprint Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data
    Dennis Falzon
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Lancet Infect Dis 13:690-7. 2013
    ..We assessed the progress towards the 2015 targets achieved by countries accounting for 90% of the estimated MDR-tuberculosis cases in the world in 2011...
  4. doi request reprint WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
    D Falzon
    Stop TB Dept, World Health Organization, Geneva 27, Switzerland
    Eur Respir J 38:516-28. 2011
    ..Controlled trials are needed to improve the quality of existing evidence, particularly on the optimal composition and duration of MDR-TB treatment regimens...
  5. doi request reprint Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF
    Karin Weyer
    Stop TB Dept, World Health Organization, Geneva, Switzerland
    Eur Respir J 42:252-71. 2013
    ....
  6. pmc Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010
    Matteo Zignol
    Stop TB Department, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
    Bull World Health Organ 90:111-119D. 2012
    ..To present a global update of drug-resistant tuberculosis (TB) and explore trends in 1994-2010...
  7. pmc Multidrug-resistant tuberculosis in children: evidence from global surveillance
    Matteo Zignol
    World Health Organization, Geneva, Switzerland
    Eur Respir J 42:701-7. 2013
    ..Of particular concern is the association found between age <15 years and MDR-TB in southern African countries with high HIV prevalence...
  8. doi request reprint Global epidemiology of tuberculosis
    Philippe Glaziou
    Stop TB Department STB, HIV AIDS, TB, Malaria and Neglected Tropical Diseases Cluster HTM, World Health Organization, Geneva, Switzerland
    Semin Respir Crit Care Med 34:3-16. 2013
    ....
  9. pmc Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing
    Matteo Zignol
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Clin Infect Dis 52:901-6. 2011
    ..Routine surveillance linked to patient care, which represents the best approach to monitor drug resistance, now has the possibility of becoming a reality even in resource-limited countries...
  10. pmc WHO guidance on electronic systems to manage data for tuberculosis care and control
    Hazim Timimi
    Stop TB Department, World Health Organization, Geneva, Switzerland
    J Am Med Inform Assoc 19:939-41. 2012
    ..The guide uses examples from eHealth projects recently implemented in Brazil, China, Pakistan and other settings to illustrate how projects in diverse settings have overcome different challenges...
  11. doi request reprint Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data
    Matteo Zignol
    Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland Electronic address
    Drug Resist Updat 16:108-15. 2013
    ..Surveillance of drug resistance has been strengthened in the WHO European Region, which has the highest proportions of MDR-TB and XDR-TB ever reported globally. More complete data are needed particularly from the Russian Federation. ..
  12. doi request reprint Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes
    Dennis Falzon
    Stop TB Dept, World Health Organization, Geneva, Switzerland
    Eur Respir J 42:156-68. 2013
    ..All data were from observational studies and methodologies varied between centres, therefore, the bias may be substantial. Better quality evidence is needed to optimise regimens. ..
  13. doi request reprint Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance
    Abigail Wright
    Stop TB Department, WHO, Geneva, Switzerland
    Lancet 373:1861-73. 2009
    ..The Global Project on Anti-Tuberculosis Drug Resistance has been gathering data since 1994. This study provides the latest data on the extent of drug resistance worldwide...
  14. doi request reprint Towards tuberculosis elimination: an action framework for low-incidence countries
    Knut Lonnroth
    Global TB Programme, World Health Organization, Geneva, Switzerland Both authors contributed equally
    Eur Respir J 45:928-52. 2015
    ..Because of increasing globalisation and population mobility, the response needs to have both national and global dimensions. ..
  15. pmc WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems
    Shanthi N Pal
    Quality Assurance and Safety Medicines, Essential Medicines and Health Products, WHO, 20 Avenue Appia 1211, Geneva 27, Switzerland
    Drug Saf 36:75-81. 2013
    ..The advantages and disadvantages of these methods and how each can be applied in clinical practice are discussed...